Characteristics and Hospitalization Details of Patients with Advanced Parkinson’s Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan
Toru Baba, Toshiki Nozaki, Shunji Toya, Hideyuki Migita, Kairi Ri, Atsushi Takeda · 2026
Read Characteristics and Hospitalization Details of Patients with Advanced Parkinson’s Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan by Toru Baba, Toshiki Nozaki, Shunji Toya, Hideyuki Migita, Kairi Ri, Atsushi Takeda (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615239.txt.
Description
Toru Baba, Toshiki Nozaki, Shunji Toya, and a team of co-authors describe the first patients in Japan treated with a new under-the-skin infusion for advanced Parkinson's disease. The therapy delivers liquid forms of the standard drug pair around the clock, smoothing the ups and downs of pills, but real-world details of who receives it were scarce.
Drawing on a large hospital database, they found just under a hundred patients started the infusion during a hospital stay in its first year. The patients were younger than typical for advanced disease and mostly still managed daily life well. Most kept taking several other Parkinson's drugs alongside, rather than first pushing pill doses higher. About a fifth stopped the infusion during their stay.
Catalog record
| CREATOR | Toru Baba, Toshiki Nozaki, Shunji Toya, Hideyuki Migita, Kairi Ri, Atsushi Takeda |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |